MiMedx Group, Inc. (MDXG)
4.52
-0.02
(-0.44%)
USD |
NASDAQ |
Sep 01, 16:00
4.52
0.00 (0.00%)
After-Hours: 20:00
MiMedx Group Research and Development Expense (Annual) : 14.70M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 14.70M |
| December 31, 2024 | 12.01M |
| December 31, 2023 | 12.36M |
| December 31, 2022 | 12.42M |
| December 31, 2021 | 17.05M |
| December 31, 2020 | 11.37M |
| December 31, 2019 | 11.14M |
| December 31, 2018 | 15.76M |
| December 31, 2017 | 17.90M |
| December 31, 2016 | 12.04M |
| Date | Value |
|---|---|
| December 31, 2015 | 8.413M |
| December 31, 2014 | 7.05M |
| December 31, 2013 | 4.844M |
| December 31, 2012 | 2.764M |
| December 31, 2011 | 2.603M |
| December 31, 2010 | 2.753M |
| March 31, 2009 | 4.023M |
| March 31, 2008 | 2.013M |
| March 31, 2007 | 0.1139M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Anika Therapeutics, Inc. | 25.77M |
| Perspective Therapeutics, Inc. | 70.96M |
| ABVC BioPharma, Inc. | 0.1211M |
| Enovis Corp. | 120.33M |
| Edwards Lifesciences Corp. | 1.079B |